BeOne gets EU nod for nasopharyngeal cancer therapy
Source: SeekingAlpha
2025-07-10 10:51:55 ET
More on BeiGene
- BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field
- BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit
- BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript
- BeOne gets FDA nod for tablet version of zanubrutinib
- Zymeworks gets China's conditional nod for BeOne-partnered cancer treatment
Read the full article on Seeking Alpha
For further details see:
BeOne gets EU nod for nasopharyngeal cancer therapy
BeiGene
NASDAQ: BEIGF
BEIGF Trading
0.0% G/L:
$23.75 Last:
100 Volume:
$23.75 Open:
BEIGF Latest News
BEIGF Stock Data
$38,603,023,416
747,457,849
N/A
299
N/A
Biotechnology & Life Sciences
Healthcare
CH
Basel
